PDF(Pubmed)
Abstract：
This review evaluates the role of ovarian and endometrial biomarkers in predicting outcomes in assisted reproductive technology (ART). It highlights established ovarian biomarkers such as the anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH), alongside emerging ones like growth differentiation factor 9 (GDF9), bone morphogenetic protein 15 (BMP15), connexin, and granulosa cell gene profiles. Additionally, the paper explores endometrial biomarkers such as ERA, BCL6, and immune markers, as well as the potential for genomic and proteomic technologies in customizing implantation. It concludes that while many of these biomarkers show promise, their clinical integration requires rigorous research and validation to confirm their safety and utility in ART.
摘要：
这篇综述评估了卵巢和子宫内膜生物标志物在预测辅助生殖技术（ART）结局中的作用。它强调了已建立的卵巢生物标志物，如抗苗勒管激素（AMH）和促卵泡激素（FSH），与生长分化因子9(GDF9)等新兴因子一起，骨形态发生蛋白15（BMP15），连接蛋白,和颗粒细胞基因图谱。此外,这篇论文探讨了子宫内膜生物标志物，如ERA，BCL6和免疫标记，以及基因组和蛋白质组学技术在定制植入方面的潜力。它的结论是，虽然许多这些生物标志物显示出希望，其临床整合需要严格的研究和验证,以确认其在ART中的安全性和实用性.
